Breaking News Instant updates and real-time market news.

IMV

IMV Inc.

$4.02

-0.125 (-3.02%)

, MRK

Merck

$82.99

0.52 (0.63%)

07:11
06/12/19
06/12
07:11
06/12/19
07:11

IMV Inc. announces updated data from SPiReL Phase 2 clinical trial

IMV Inc. (IMV) announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV's lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck's (MRK) checkpoint inhibitor Keytruda. The trial is designed to evaluate the safety and efficacy of the combination immunotherapy in patients with persistent or recurrent/refractory diffuse large B-cell lymphoma, or DLBCL. At the first "on treatment" assessment, five of the first six patients demonstrated clinical benefit, including four patients with tumor regressions. Two patients reached a complete radiological response, one a partial response, and two had stable disease while on study. In addition, the combination continued to demonstrate an acceptable safety profile. At the time of data cut-off for this analysis, 11 patients were enrolled in the trial. Efficacy data from the first six evaluable patients are based on modified Cheson criteriai. Two patients achieved a complete radiological response. These patients have shown the best survivin specific T cell responses to DPX-Survivac among the analyzed samples. One patient with a complete response, or CR, has completed the one-year study period. One patient achieved a partial response, or PR, at first "on treatment" scan Two patients have reached stable disease. Each of these patients has remained progression free for six and eight months while on treatment. One patient with bulky disease progressed at first scan. Two subjects are not evaluable, coming off trial at day 7 and day 28. The treatment combination appears to be well-tolerated with only two serious adverse events related to treatment. Radiological results from three additional patients are pending

IMV

IMV Inc.

$4.02

-0.125 (-3.02%)

MRK

Merck

$82.99

0.52 (0.63%)

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

IMV IMV Inc.
$4.02

-0.125 (-3.02%)

03/25/19
HCWC
03/25/19
INITIATION
Target $11.5
HCWC
Buy
IMV Inc. initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started IMV Inc. with a Buy rating and $11.50 price target. The analyst has a favorable view of the company's proprietary DPX platform technology, which he says is a cancer vaccine-like therapeutic approach with key differences.
05/29/19
RILY
05/29/19
INITIATION
Target $11
RILY
Buy
IMV Inc. initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani started IMV Inc. with a Buy rating and $11 price target. The company is developing an off-the-shelf immunotherapy, DPX-Survivac, for ovarian and other hard-to-treat cancers, and the early results have been "encouraging," Mamtani tells investors in a research note.
05/29/19
05/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), Facebook (FB), and Twitter (TWTR) were initiated with a Buy at Pivotal Research, while Alphabet (GOOG, GOOGL), Pinterest (PINS), and Snap (SNAP) were initiated with a Hold. 2. Anchiano Therapeutics (ANCN) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Neutral at DA Davidson. 4. National Vision (EYE) initiated with a Buy at Berenberg. 5. IMV Inc. (IMV) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$82.99

0.52 (0.63%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.

TODAY'S FREE FLY STORIES

12:10
06/25/19
06/25
12:10
06/25/19
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY fell…

AGN

Allergan

$164.20

34.55 (26.65%)

, ABBV

AbbVie

$66.78

-11.63 (-14.83%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have slid in…

AGN

Allergan

$164.20

34.55 (26.65%)

ABBV

AbbVie

$66.78

-11.63 (-14.83%)

TMUS

T-Mobile

$74.93

-0.61 (-0.81%)

S

Sprint

$6.86

(0.00%)

DISH

Dish

$37.93

-0.66 (-1.71%)

LEN

Lennar

$48.75

-2.66 (-5.17%)

PYX

Pyxus

$16.70

3.28 (24.44%)

GRUB

GrubHub

$75.31

3.26 (4.52%)

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

BHF

Brighthouse Financial

$32.74

-5.36 (-14.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 09

    Jul

  • 16

    Sep

DLTR

Dollar Tree

$109.86

-2.86 (-2.54%)

12:08
06/25/19
06/25
12:08
06/25/19
12:08
Hot Stocks
Dollar Tree director Thomas Saunders sells over $1.6M in company shares »

Dollar Tree director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$13.72

-0.2 (-1.44%)

12:05
06/25/19
06/25
12:05
06/25/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$5.85

-1.23 (-17.37%)

12:02
06/25/19
06/25
12:02
06/25/19
12:02
Recommendations
Aldeyra analyst commentary at Stifel »

Stifel says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UNH

UnitedHealth

$249.06

-0.59 (-0.24%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Periodicals
UnitedHealth buys PatientsLikeMe after scrutiny over Chinese investor, CNBC says »

According to a story out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

RGS

Regis

$16.62

-1.15 (-6.47%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Regis falls -6.4% »

Regis is down -6.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$14.36

-1.02 (-6.63%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
EQT Corporation falls -6.6% »

EQT Corporation is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ABBV

AbbVie

$66.64

-11.77 (-15.01%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
AbbVie falls -15.1% »

AbbVie is down -15.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 16

    Sep

USNA

Usana

$78.92

6.515 (9.00%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Usana rises 8.6% »

Usana is up 8.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYX

Pyxus

$16.40

2.98 (22.21%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Pyxus rises 23.0% »

Pyxus is up 23.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$163.99

34.34 (26.49%)

12:00
06/25/19
06/25
12:00
06/25/19
12:00
Hot Stocks
Allergan rises 26.6% »

Allergan is up 26.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

, AMRN

Amarin

$18.55

0.12 (0.65%)

11:59
06/25/19
06/25
11:59
06/25/19
11:59
Periodicals
Acasti Pharma mentioned positively by Seeking Alpha contributor »

Seeking Alpha contributor…

ACST

Acasti Pharma

$1.03

0.02 (1.98%)

AMRN

Amarin

$18.55

0.12 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Sep

AMAT

Applied Materials

$42.33

(0.00%)

11:55
06/25/19
06/25
11:55
06/25/19
11:55
Options
Applied Materials put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

ACER

Acer Therapeutics

$4.34

-14.83 (-77.36%)

11:52
06/25/19
06/25
11:52
06/25/19
11:52
Downgrade
Acer Therapeutics rating change at Raymond James »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

KNX

Knight-Swift

$30.43

0.37 (1.23%)

11:45
06/25/19
06/25
11:45
06/25/19
11:45
Options
Knight Transportation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

11:45
06/25/19
06/25
11:45
06/25/19
11:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

AMZN

Amazon.com

$1,890.97

-22.46 (-1.17%)

, MSFT

Microsoft

$134.89

-2.91 (-2.11%)

11:44
06/25/19
06/25
11:44
06/25/19
11:44
On The Fly
Microsoft slips as analyst sees stock 'materially overvalued' as Azure 'not AWS' »

Saying that Microsoft…

AMZN

Amazon.com

$1,890.97

-22.46 (-1.17%)

MSFT

Microsoft

$134.89

-2.91 (-2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

WPX

WPX Energy

$11.01

-0.02 (-0.18%)

11:35
06/25/19
06/25
11:35
06/25/19
11:35
Options
WPX Energy put volume heavy and directionally bearish »

Bearish flow noted in WPX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$51.10

-0.31 (-0.60%)

11:34
06/25/19
06/25
11:34
06/25/19
11:34
Hot Stocks
Lennar remains confident in reaching FY19 home delivery target of 50,000 homes »

Expects margins to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

LEN

Lennar

$50.94

-0.47 (-0.91%)

11:33
06/25/19
06/25
11:33
06/25/19
11:33
Earnings
Lennar sees Q3 EPS $1.25-$1.35, consensus $1.52 »

Sees Q3 new orders of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

11:30
06/25/19
06/25
11:30
06/25/19
11:30
General news
Treasury announced a $75 B batch of auctions for Thursday »

Treasury announced a $75…

ACER

Acer Therapeutics

$4.31

-14.86 (-77.52%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Downgrade
Acer Therapeutics rating change  »

Acer Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CLDR

Cloudera

$5.53

0.005 (0.09%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Options
Cloudera call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CODI

Compass Diversified

$19.00

0.345 (1.85%)

11:25
06/25/19
06/25
11:25
06/25/19
11:25
Conference/Events
Compass Diversified to host investor & analyst meeting »

Investor & Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.